浙江东方基因生物制品股份有限公司2025年年度业绩预亏公告
Shang Hai Zheng Quan Bao·2026-01-29 19:44

Group 1 - The company expects a net loss attributable to shareholders of the parent company for the year 2025, estimated at -5.23 billion yuan [3] - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be -5.58 billion yuan [4] - The performance forecast is based on preliminary calculations and has not been audited by a registered accountant [5] Group 2 - In the same period last year, the total profit was -5.85 billion yuan, with a net profit attributable to shareholders of the parent company at -5.29 billion yuan [6] - The earnings per share for the previous year were -2.69 yuan [7] Group 3 - The main reasons for the expected loss in 2025 include significant investments in the strategic development of various technology platforms, reduced contributions from foreign exchange losses and interest income, and increased depreciation and impairment losses [8] - Normal investment income from financial management activities had a non-operating impact during the reporting period [9]

ZJOFHC-浙江东方基因生物制品股份有限公司2025年年度业绩预亏公告 - Reportify